SCHEMBL1798372

SCHEMBL1798372

CC1(C)O[C@@H]2[C@H](O1)[C@@H](CO)O[C@H]2n1cnc2c(C#Cc3ccccc3)ncnc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.65
PI4K2B Q8TCG2 1/20 0.65
PI4K2A Q9BTU6 1/20 0.65
PI4KB Q9UBF8 1/20 0.65
LMNA P02545 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
ALDH1A1 P00352 2/20 0.48
RXFP1 Q9HBX9 2/20 0.47
ADORA3 P0DMS8 9/20 0.46
ADORA2A P29274 5/20 0.46
ADORA1 P30542 5/20 0.46
ADORA2B P29275 2/20 0.46
SLC29A1 Q99808 3/20 0.45
TP53 P04637 1/20 0.45
P2RX1 P51575 1/20 0.45
P2RX3 P56373 1/20 0.45
P2RX4 Q99571 1/20 0.45
GLA P06280 1/20 0.44
PMP22 Q01453 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11890143 1.00 PI4KA (0.65) PI4KAPI4K2BPI4K2API4KBLMNA
SCHEMBL1796244 0.87 RXFP1 (0.50) PI4KAPI4K2BPI4K2API4KBLMNA
SCHEMBL1798087 0.85 RXFP1 (0.61) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL1945010 0.85 RXFP1 (0.49) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL2292923 0.81 ADORA3 (0.71) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL2291671 0.81 PI4KA (0.80) PI4KAPI4K2BPI4K2API4KBLMNA
SCHEMBL17889871 0.81 PI4KA (0.41) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL1798740 0.81 PI4KA (0.41) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL5508444 0.80 LMNA (0.69) PI4KAPI4K2BPI4K2API4KBLMNA
SCHEMBL1799458 0.80 PI4KA (0.66) PI4KAPI4K2BPI4K2API4KBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070798-A1 Inhibitors of E1 activating enzymes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-11 US disclosed
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. 2018-03-29 US disclosed
US-20170073367-A9 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENIUM PHARMACEUTICALS, INC. 2017-03-16 US disclosed
US-20160194348-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARM INC (US) 2016-07-07 US disclosed
US-20140256668-A9 SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-11 US disclosed
US-20130338094-A1 SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-12-19 US disclosed
EP-1848718-B1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARM INC (US) 2012-08-01 EP disclosed
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed
US-7951810-B2 Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-05-31 US disclosed
US-20060189636-A1 Inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 PI4KA 1455/4885PI4K2B 2027/4885PI4K2A 1655/4885
US-20170073367-A9 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 PI4KA 1455/4885PI4K2B 2027/4885PI4K2A 1655/4885
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES ECE1, RNASE1, RCE1 PI4KA 1991/4885PI4K2B 2891/4885PI4K2A 2431/4885
US-20140256668-A9 SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES DPYD, CCND3, POLD3 PI4KA 1546/4885PI4K2B 704/4885PI4K2A 804/4885
US-20160194348-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 PI4KA 1455/4885PI4K2B 2027/4885PI4K2A 1655/4885
US-20210070798-A1 Inhibitors of E1 activating enzymes ECE1, RNASE1, RCE1 PI4KA 1991/4885PI4K2B 2891/4885PI4K2A 2431/4885
US-20130338094-A1 SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES DPYD, CCND3, POLD3 PI4KA 1546/4885PI4K2B 704/4885PI4K2A 804/4885
US-20060189636-A1 Inhibitors of E1 activating enzymes ECE1, RNASE1, RCE1 PI4KA 1991/4885PI4K2B 2891/4885PI4K2A 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.